Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies

Hepatocellular carcinoma (HCC) ranks among the most rapidly evolving cancers in the Western world. The majority of HCCs develop on the basis of a chronic inflammatory liver damage that predisposes liver cancer development and leads to deregulation of multiple cellular signaling pathways. The resulting dysbalance between uncontrolled proliferation and impaired predisposition to cell death with consecutive failure to clear inflammatory damage is a key driver of malignant transformation. Therefore, resistance to death signaling accompanied by metabolic changes as well as failed immunological clearance of damaged pre-neoplastic hepatocytes are considered hallmarks of hepatocarcinogenesis. Hereby, the underlying liver disease, the type of liver damage and individual predisposition to apoptosis determines the natural course of the disease as well as the therapeutic response. Here, we will review common and individual aspects of cell death pathways in hepatocarcinogenesis with a particular emphasis on regulatory networks and key molecular alterations. We will further delineate the potential of targeting cell death-related signaling as a viable therapeutic strategy to improve the outcome of HCC patients.

[1]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[2]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[3]  J. Marquardt,et al.  Context-Dependent Role of NF-κB Signaling in Primary Liver Cancer—from Tumor Development to Therapeutic Implications , 2019, Cancers.

[4]  Wei Li,et al.  Global liver disease burdens and research trends: Analysis from a Chinese perspective. , 2019, Journal of hepatology.

[5]  M. Karin,et al.  The Fire within: Cell-Autonomous Mechanisms in Inflammation-Driven Cancer. , 2019, Cancer cell.

[6]  Li Jin,et al.  The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. , 2019, Journal of hepatology.

[7]  Elizabeth J. Osterlund,et al.  Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2 , 2019, eLife.

[8]  D. Pollyea,et al.  Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective? , 2019, Current opinion in hematology.

[9]  A. Vogel,et al.  The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies , 2019, Targeted Oncology.

[10]  T. Kipps,et al.  Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Seki,et al.  Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets , 2019, Seminars in Liver Disease.

[12]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[13]  Y. Funahashi,et al.  Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model , 2018, Cancer science.

[14]  Austin E. Gillen,et al.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia , 2018, Nature Medicine.

[15]  O. Ohara,et al.  Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC , 2018, Cell.

[16]  J. Fernandez-Checa,et al.  Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease , 2018, Hepatology communications.

[17]  T. Luedde,et al.  Apoptosis and necroptosis in the liver: a matter of life and death , 2018, Nature Reviews Gastroenterology & Hepatology.

[18]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[19]  G. Gordon,et al.  Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[21]  Marco Montillo,et al.  Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia , 2018, The New England journal of medicine.

[22]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[23]  G. Ghanem,et al.  PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies , 2017, Cancers.

[24]  K. Döhner,et al.  Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML , 2017, Clinical Cancer Research.

[25]  S. Thorgeirsson,et al.  Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas , 2017, Oncotarget.

[26]  T. Luedde,et al.  RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. , 2017, Cancer cell.

[27]  E. Pérez-Payá,et al.  Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes , 2016, Proceedings of the National Academy of Sciences.

[28]  A. Canbay,et al.  Cell death mechanisms in human chronic liver diseases: a far cry from clinical applicability. , 2016, Clinical science.

[29]  B. Zee,et al.  Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) , 2016, American journal of clinical oncology.

[30]  T. Rodt,et al.  Serum Cell Death Biomarker Mirrors Liver Cancer Regression after Transarterial Chemoembolisation , 2016, Zeitschrift für Gastroenterologie.

[31]  S. R. Kopalli,et al.  Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents , 2016, Expert opinion on therapeutic patents.

[32]  M. Omary,et al.  Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver , 2016, Hepatology.

[33]  Ji Luo,et al.  NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis , 2016, Nature.

[34]  I. Fabregat,et al.  Apoptosis in liver carcinogenesis and chemotherapy. , 2015, Hepatic oncology.

[35]  S. Thorgeirsson,et al.  Functional and genetic deconstruction of the cellular origin in liver cancer , 2015, Nature Reviews Cancer.

[36]  M. Manns,et al.  The BH3‐only protein BID impairs the p38‐mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice , 2015, Hepatology.

[37]  A. Wree,et al.  Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation , 2015, Cell Death and Differentiation.

[38]  L. Walensky,et al.  Inhibition of Pro-apoptotic BAX by a noncanonical interaction mechanism. , 2015, Molecular cell.

[39]  Karen Blyth,et al.  Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death , 2015, Molecular cell.

[40]  S. Frank,et al.  Differential retrotranslocation of mitochondrial Bax and Bak , 2015, The EMBO journal.

[41]  J. Zucman‐Rossi,et al.  Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making , 2014, Seminars in Liver Disease.

[42]  M. Karin,et al.  ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. , 2014, Cancer cell.

[43]  J. Trojan,et al.  Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. , 2013, Journal of hepatology.

[44]  G. Giovinazzo,et al.  Myc-driven endogenous cell competition in the early mammalian embryo , 2013, Nature.

[45]  S. Friedman,et al.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. , 2013, Gastroenterology.

[46]  E. Albano,et al.  NF-κB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses. , 2013, Clinical science.

[47]  Z. Çakır,et al.  The C-terminal helix of Bcl-xL mediates Bax retrotranslocation from the mitochondria , 2012, Cell Death and Differentiation.

[48]  A. Letai,et al.  Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[49]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[50]  I. Fabregat,et al.  Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli , 2012, Journal of cellular physiology.

[51]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[52]  Nico Tjandra,et al.  Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol , 2011, Cell.

[53]  T. Luedde,et al.  NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.

[54]  S. Thorgeirsson,et al.  Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. , 2010, Cancer research.

[55]  A. Letai,et al.  Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes , 2010, Proceedings of the National Academy of Sciences.

[56]  Thomas J. Fuchs,et al.  TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. , 2010, Cancer cell.

[57]  Derek W. Yecies,et al.  MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts , 2009, The Journal of cell biology.

[58]  R. Hotchkiss,et al.  Cell death. , 2009, The New England journal of medicine.

[59]  T. Luedde,et al.  p38α MAPK inhibits JNK activation and collaborates with IκB kinase 2 to prevent endotoxin‐induced liver failure , 2008, EMBO reports.

[60]  N. Tjandra,et al.  BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.

[61]  A. Elsharkawy,et al.  Nuclear factor‐κB and the hepatic inflammation‐fibrosis‐cancer axis , 2007 .

[62]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[63]  Ronald A. DePinho,et al.  Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.

[64]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[65]  N. Chen,et al.  First-in-class pan caspase inhibitor developed for the treatment of liver disease. , 2005, Journal of medicinal chemistry.

[66]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[67]  M. Karin,et al.  Inhibition of JNK activation through NF-κB target genes , 2001, Nature.

[68]  H. Pahl Activators and target genes of Rel/NF-κB transcription factors , 1999, Oncogene.

[69]  B. Corfe,et al.  Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis , 1999, The Journal of cell biology.

[70]  Jean-Claude Martinou,et al.  Bax-induced Cytochrome C Release from Mitochondria Is Independent of the Permeability Transition Pore but Highly Dependent on Mg2+ Ions , 1998, The Journal of cell biology.

[71]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[72]  Y. Hsu,et al.  Bax in Murine Thymus Is a Soluble Monomeric Protein That Displays Differential Detergent-induced Conformations* , 1998, The Journal of Biological Chemistry.

[73]  Z. Oltvai,et al.  Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[74]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[75]  J. Sulston,et al.  Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. , 1977, Developmental biology.

[76]  J. Shields,et al.  Genes or environment , 1976, Nature.

[77]  Samir Guglani Death , 1890, The Lancet.

[78]  M. Pasparakis,et al.  RIP Kinases in Liver Cell Death, Inflammation and Cancer. , 2019, Trends in molecular medicine.

[79]  P. Galle,et al.  Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. , 2012, Journal of hepatology.

[80]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[81]  J. Risk,et al.  Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets , 2007, Cell Death and Differentiation.

[82]  J Salvage,et al.  A matter of life and death. , 1981, Nursing times.